Page 8 - 45337c10 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from 45337c10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In 45337c10 Today - Breaking & Trending Today
Polar Capital Holdings Plc decreased its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 0.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,090,000 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the […] ....
Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 1,914,311 shares were traded during trading, an increase of 10% from the previous session’s volume of 1,744,265 shares.The stock last traded at $53.92 and had previously closed at $53.39. Analyst Ratings Changes Several analysts have recently issued reports […] ....
Renaissance Technologies LLC decreased its holdings in Incyte Co. (NASDAQ:INCY – Free Report) by 13.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,828,189 shares of the biopharmaceutical company’s stock after selling 774,244 shares during the quarter. Renaissance Technologies LLC owned […] ....
Incyte (NASDAQ:INCY – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Truist Financial in a report issued on Wednesday, Benzinga reports. They currently have a $91.00 target price on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 70.48% from the stock’s current price. A number […] ....
E Fund Management Co. Ltd. lifted its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 30.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,167 shares of the biopharmaceutical company’s stock after acquiring an additional 2,120 […] ....